SciSparc Ltd. Regains Compliance With Nasdaq Minimum Bid Price Notification
SciSparc Ltd. Regains Compliance With Nasdaq Minimum Bid Price Notification
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc's focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol (CBD): SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seeds' oil-based products on the Amazon.com Marketplace.Tel Aviv, Oct. 16, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Company"), reported the receipt of a formal notification from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Listing Rule 5550(a)(2), which requires the Company's ordinary shares to maintain a minimum bid price of $1.00 per share.
特拉維夫，2023年10月16日(環球網)--納斯達克：SPRC是一家專注於開發治療中樞神經系統疾病療法的專業臨床階段製藥公司(以下簡稱“公司”)，該公司報告收到納斯達克股票市場有限責任公司(“納斯達克”)的正式通知，稱公司已重新遵守上市規則第5550(A)(2)條，該規則要求公司普通股維持每股1.00美元的最低出價。
The Nasdaq staff made this determination of compliance after the closing bid price of the Company's ordinary shares was at $1.00 per share or greater for the prior 10 consecutive business days. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) and Nasdaq considers the prior bid price deficiency matter now closed.
納斯達克工作人員是在公司普通股連續10個工作日的收盤價為每股1.00美元或更高後做出這一合規判斷的。因此，本公司已恢復遵守納斯達克上市規則第5550(A)(2)條，而納斯達克認為先前的投標價格不足事宜現已結束。
About SciSparc Ltd. (Nasdaq:SPRC):
關於本公司(納斯達克市場代碼：SPRC)：
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc's focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol (CBD): SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seeds' oil-based products on the Amazon.com Marketplace.
SciSparc有限公司是一家專業的臨床階段製藥公司，由一支經驗豐富的高級管理人員和科學家團隊領導。本組織的重點是創建和加強以大麻類藥物為基礎的技術和資產組合。在這一重點上，該公司目前從事以下基於THC和/或非精神活性大麻二醇(CBD)的藥物開發計劃：用於治療抽動症的SCI-110，用於治療阿爾茨海默病和激動症的SCI-110；用於治療疼痛的SCI-160；以及用於治療自閉症譜系障礙和癲癇持續狀態的SCI-210。該公司還擁有一家子公司的控股權，該子公司的業務重點是在亞馬遜市場上銷售大麻種子的油基產品。
For further information please refer to information available on the Company's website:
欲瞭解更多資訊，請參閱公司網站上的資訊：
Investor Contact:
IR@scisparc.com
Tel: +972-3-6167055
投資者聯繫方式：
郵箱：ir@scisparc.com
電話：+9723-6167055